LIFECORE BIOMEDICAL, INC. Financing Receivable, Allowance for Credit Loss
LIFECORE BIOMEDICAL, INC. (LFCR) had Financing Receivable, Allowance for Credit Loss of $282.00 thousand as of 2021-02-28, per its 10-Q filed 2021-04-08.
Discontinued › Balance Sheet › Assets
us-gaap:FinancingReceivableAllowanceForCreditLosses · last filed 2021-04-08
- 2021-02-28: Financing Receivable, Allowance for Credit Loss $282.00K.
- 2020-11-29: Financing Receivable, Allowance for Credit Loss $277.00K.
- 2020-08-30: Financing Receivable, Allowance for Credit Loss $304.00K.
- 2020-05-31: Financing Receivable, Allowance for Credit Loss $438.00K.
| Period end | Financing Receivable, Allowance for Credit Loss |
|---|---|
| 2021-02-28 | $282.00K 10-Q · filed 2021-04-08 |
| 2020-11-29 | $277.00K 10-Q · filed 2021-01-07 |
| 2020-08-30 | $304.00K 10-Q · filed 2020-10-07 |
| 2020-05-31 | $438.00K 10-Q · filed 2021-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |